Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p395 | Osteoporosis: treatment | ECTS2016

Acute kidney injury after a single intravenous zoledronic acid administration in patients with osteoporosis

Cipriani Cristiana , Clementelli Carolina , Fassino Valeria , Manai Rizieri , Danese Vittoria , Cecchetti Veronica , Ferrone Federica , Pepe Jessica , Minisola Salvatore

Safety data on zoledronic acid (ZA) administration for osteoporosis suggest potential kidney toxicity; indeed, it is not indicated in patients with impaired renal function. PatientsÂ’ clinical monitoring usually includes glomerular filtration rate (GFR) evaluation; no study addressed the issue of the early kidney injury. We evaluated the early (within 3 months) effect of iv ZA on renal function defining the potential role of AKI biomarkers in unveiling subtle damage.<p...

ba0003pp314 | Osteoporosis: treatment | ECTS2014

The effect of risedronate on hypogonadal osteoporotic HIV males treated with highly active anti-retroviral therapy: a pilot study

Pepe Jessica , Isidori Andrea M , Falciano Mario , Iaiani Giancarlo , Salotti Alessandra , Diacinti Daniele , Del Fiacco Romano , Sbardella Emilia , Cipriani Cristiana , Piemonte Sara , Raimo Orlando , D'angelo Antonella , Romagnoli Elisabetta , Lenzi Andrea , Minisola Salvatore

Objective: We evaluated the effect of risedronate on BMD and bone turnover markers in HIV infected osteoporotic males, according to their gonadal status.Methods: 41 HIV patients treated with highly active anti-retroviral therapy (HAART) were followed for 24 months and divided into two groups: patients with osteoporosis or osteopenia with fractures (Group A, n=20) and those without (Group B, n=21). Group A and B were fur...